Keith Flaherty, M.D., is a co-founding advisor of Gliomic Therapeutics, Inc. He serves director of clinical cancer research and the Richard Saltonstall Endowed Chair in Oncology at Mass General Cancer Center, a founding member of Mass General Brigham. He is also a professor of medicine at Harvard Medical School, an associate member of the Broad Institute of MIT and Harvard, and the President of the American Association for Cancer Research. Dr. Flaherty has been honored with numerous awards throughout his career, most notably the OncLive Giants of Cancer Care Award for Melanoma (2020), the Society for Melanoma Research Lifetime Achievement Award (2019), the National Cancer Institute Michaele C. Christian Oncology Development Lectureship and Award (2015), the Mass General Cancer Center Harrison Clinical Research Award (2013), and the Peter Fink Memorial Lectureship (2013). He served as co-founder of multiple successful targeted oncology companies, including Loxo Oncology (acquired for $8.0 billion) and Scorpion Therapeutics (acquired for $2.5 billion). Dr. Flaherty earned his undergraduate degree in neurobiology at Yale University and his medical degree at Johns Hopkins University.